okyopharma.com - שווי פירמה כולל OKYO

OKYO Pharma Limited (OKYO) maintains a high reputation for developing advanced ophthalmological treatments, validated by successful trials of dry eye drops. The business focuses on developing inflammation therapies and combating corneal pain. The company is currently in an expansion phase, targeting a multi-billion dollar market segment. This price chart confirms these data, with an Enterprise Value of 58.13.

The potential of OKYO Pharma Limited (OKYO) to commercialize the OK-101 drug determines the investment attractiveness of its assets. The enterprise value metric sums market capitalization and net debt, reflecting the total cost of acquiring the business. This calculation allows for an assessment of the company's real price, stripped of the influence of cash reserves. It is critical for investors to track this indicator to determine the fundamental overvaluation of the issuer. The enterprise value trend captures the company's market value in real-time.